成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Home Cart Sign in  
Chemical Structure| 417716-92-8 Chemical Structure| 417716-92-8

Structure of Lenvatinib
CAS No.: 417716-92-8

Chemical Structure| 417716-92-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

{[proInfo.proName]}

CAS No.: 417716-92-8

,{[proInfo.pro_purity]}

Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that targets VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, showing potent antitumor activities.

Synonyms: E7080; ER-203492-00

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Lenvatinib

CAS No. :417716-92-8
Formula : C21H19ClN4O4
M.W : 426.85
SMILES Code : O=C(C1=C(OC)C=C2N=CC=C(OC3=CC=C(NC(NC4CC4)=O)C(Cl)=C3)C2=C1)N
Synonyms :
E7080; ER-203492-00
MDL No. :MFCD16038644
InChI Key :WOSKHXYHFSIKNG-UHFFFAOYSA-N
Pubchem ID :9823820

Safety of Lenvatinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Lenvatinib

RTK

Isoform Comparison

Biological Activity

Target
  • VEGFR1

    VEGFR1/FLT1, IC50:22 nM

  • VEGFR3

    VEGFR3/FLT4, IC50:5.2 nM

  • VEGFR2

    VEGFR2/KDR, IC50:4.0 nM

  • FGFR1

    FGFR1, IC50:46 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
TPC-1 15 nM Establish lenvatinib-resistant cell lines and analyze resistance mechanisms PMC9459297
FRO 30 nM Establish lenvatinib-resistant cell lines and analyze resistance mechanisms PMC9459297
SMMC-7721 10 μM 24 h To evaluate the effect of Lenvatinib on STOML2 expression, it was found that Lenvatinib significantly upregulated STOML2 expression PMC7807703
HCCLM3 10 μM 24 h To evaluate the effect of Lenvatinib on STOML2 expression, it was found that Lenvatinib significantly upregulated STOML2 expression PMC7807703
HepG2 cells 80 μM 14 days To identify key genes associated with Lenvatinib resistance, it was found that DUSP4 deficiency enhanced Lenvatinib resistance and maintained cell proliferation, survival, and migration ability. PMC9295068
Huh7 cells 20 μM 24 h To validate the role of DUSP4 in Lenvatinib resistance, it was found that DUSP4 deficiency enhanced Lenvatinib resistance and maintained cell proliferation, survival, and migration ability. PMC9295068
Hep3B cells 10 μM 48 h To evaluate the effect of Lenvatinib on apoptosis in Hep3B cells, results showed that Lenvatinib induced apoptosis. PMC8891362
Hep3B/CSQT-2 cells 2.5 μM 7 days To evaluate the effect of Lenvatinib on colony growth in Hep3B/CSQT-2 cells, results showed that Lenvatinib inhibited colony growth. PMC8891362
Caki-1 cells 20 μM 72 h To study the effect of Lenvatinib on the viability of renal cancer cells, results showed that Lenvatinib significantly decreased the viability of renal cancer cells PMC9104196
786-O cells 20 μM 72 h To study the effect of Lenvatinib on the viability of renal cancer cells, results showed that Lenvatinib significantly decreased the viability of renal cancer cells PMC9104196
A-498 cells 20 μM 72 h To study the effect of Lenvatinib on the viability of renal cancer cells, results showed that Lenvatinib significantly decreased the viability of renal cancer cells PMC9104196
HepG2 cells 20 or 40 μM 48 h To evaluate the cytotoxicity of Lenvatinib on HepG2 cells, the results showed that 20 μM of Lenvatinib had a limited role in inducing apoptosis. PMC9936410
Huh7 cells 20 or 40 μM 48 h To evaluate the cytotoxicity of Lenvatinib on Huh7 cells, the results showed that both 20 and 40 μM of Lenvatinib significantly induced apoptosis. PMC9936410
PLC/PRF5 cells 20 or 40 μM 48 h To evaluate the cytotoxicity of Lenvatinib on PLC/PRF5 cells, the results showed that 20 μM of Lenvatinib had a limited role in inducing apoptosis. PMC9936410
Hep3B cells 20 or 40 μM 48 h To evaluate the cytotoxicity of Lenvatinib on Hep3B cells, the results showed that both 20 and 40 μM of Lenvatinib significantly induced apoptosis. PMC9936410
HCCLM3 0.00001, 0.0001, 0.001, 0.01, 1, 10 and 100 μM 72 h To evaluate the sensitivity of HCC cells to Lenvatinib, the results showed that HCC cells with high TBC1D31 expression significantly increased resistance to Lenvatinib. PMC11516053
HepG2 0.00001, 0.0001, 0.001, 0.01, 1, 10 and 100 μM 72 h To evaluate the sensitivity of HCC cells to Lenvatinib, the results showed that HCC cells with high TBC1D31 expression significantly increased resistance to Lenvatinib. PMC11516053

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c-nu nude mice TPC-1/LR tumor xenograft model oral 6 mg/kg once daily for 9 days Evaluate the antitumor effect of lenvatinib and lapatinib combination on TPC-1/LR tumors PMC9459297
Mice 8505 C cell xenograft model Oral 25 mg/kg Once daily for 3 weeks To evaluate the efficacy of Lenvatinib in combination with BRAF inhibitor PLX4720 for the treatment of BRAF-mutant thyroid cancer. The results showed that Lenvatinib monotherapy significantly suppressed tumor growth, and the inhibitory effect of PLX4720 was further enhanced when combined with Lenvatinib. PMC11127897
nude mice HCCLM3 xenograft model intraperitoneal injection 5 mg/kg or 10 mg/kg daily until the end of the experiment To evaluate the inhibitory effect of Lenvatinib on HCC growth, it was found that Lenvatinib significantly suppressed tumor growth, and the combination with hydroxychloroquine was more effective PMC7807703
BALB/C nude mice Xenograft tumor model Oral gavage 30 mg/kg/d Daily for 4 weeks To evaluate the effect of DUSP4 deficiency on Lenvatinib resistance, it was found that DUSP4 deficiency impaired the anti-tumor effects of Lenvatinib and enhanced tumor growth. PMC9295068
Mice Hepa1-6 hepatoma orthotopic model Oral 10 mg/kg Once daily for two weeks To evaluate the anti-angiogenic effects of Lenvatinib on tumor angiogenesis, the results showed that Lenvatinib significantly inhibited tumor angiogenesis. PMC10831275
Nude mice PDX model Intraperitoneal injection 60 mg/kg Daily for 24 days To evaluate the effect of Lenvatinib on tumor growth in PDX model, results showed that Lenvatinib significantly inhibited tumor growth. PMC8891362
BALB/c nude mice Huh7 cell xenograft model Intragastric administration 10 or 30 mg/kg Once daily for two weeks To evaluate the anti-tumor effect of Lenvatinib in vivo on the Huh7 cell xenograft model, the results showed that both 10 and 30 mg/kg/d of Lenvatinib significantly inhibited tumor growth. PMC9936410
Nude mice HCC cell line-derived xenograft model Oral 4 mg/kg Every 5 days until tumor volume reaches 1500 mm3 To evaluate the effect of TBC1D31 knockdown on the anti-tumor efficacy of Lenvatinib, the results showed that TBC1D31 knockdown significantly increased the sensitivity of HCCLM3 cells to Lenvatinib. PMC11516053

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT06435013 Hepatocellular Carcinoma|Lenva... More >>tinib Less << COMPLETED 2024-05-20 Cancer Center Sun Yat-sen Univ... More >>ersity, Guangzhou, Guangdong, 510060, China Less <<
NCT01136967 Unresectable Stage III|Stage I... More >>V Melanoma Less << PHASE2 COMPLETED 2025-11-14 Birmingham, Alabama, United St... More >>ates|Tucson, Arizona, United States|Los Angeles, California, United States|San Francisco, California, United States|Aurora, Colorado, United States|Boulder, Colorado, United States|Colorado Springs, Colorado, United States|Denver, Colorado, United States|Lakewood, Colorado, United States|Littleton, Colorado, United States|Lone Tree, Colorado, United States|Longmont, Colorado, United States|Parker, Colorado, United States|Thornton, Colorado, United States|Bonita Springs, Florida, United States|Bradenton, Florida, United States|Cape Coral, Florida, United States|Clearwater, Florida, United States|Englewood, Florida, United States|Fort Myers, Florida, United States|Gainesville, Florida, United States|Naples, Florida, United States|North Port, Florida, United States|Orlando, Florida, United States|Palm Harbor, Florida, United States|Port Charlotte, Florida, United States|Sarasota, Florida, United States|Sebring, Florida, United States|Tampa, Florida, United States|Venice, Florida, United States|Louisville, Kentucky, United States|Boston, Massachusetts, United States|Detroit, Michigan, United States|Burnsville, Minnesota, United States|Coon Rapids, Minnesota, United States|Edina, Minnesota, United States|Fridley, Minnesota, United States|Maplewood, Minnesota, United States|Minneapolis, Minnesota, United States|Saint Paul, Minnesota, United States|Woodbury, Minnesota, United States|Southaven, Mississippi, United States|Saint Louis, Missouri, United States|Henderson, Nevada, United States|Las Vegas, Nevada, United States|Lebanon, New Hampshire, United States|Morristown, New Jersey, United States|New York, New York, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Eugene, Oregon, United States|Portland, Oregon, United States|Springfield, Oregon, United States|Tualatin, Oregon, United States|Bethlehem, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Bartlett, Tennessee, United States|Franklin, Tennessee, United States|Gallatin, Tennessee, United States|Germantown, Tennessee, United States|Hermitage, Tennessee, United States|Lebanon, Tennessee, United States|Memphis, Tennessee, United States|Murfreesboro, Tennessee, United States|Nashville, Tennessee, United States|Smyrna, Tennessee, United States|Bedford, Texas, United States|Dallas, Texas, United States|Grapevine, Texas, United States|Houston, Texas, United States|Arlington, Virginia, United States|Fairfax, Virginia, United States|Gainesville, Virginia, United States|Leesburg, Virginia, United States|Winchester, Virginia, United States|Woodbridge, Virginia, United States|Vancouver, Washington, United States|Madison, Wisconsin, United States|Adelaide, Australia|Malvern, Australia|Newcastle, Australia|North Sydney, Australia|Perth, Australia|Westmead, Australia|Essen, Germany|Hannover, Germany|Heidelberg, Germany|Kiel, Germany|Mainz, Germany|Tubingen, Germany|Glasgow, United Kingdom|London, United Kingdom|Nottingham, United Kingdom|Surrey, United Kingdom Less <<
NCT02780310 Adenoid Cystic Carcinoma PHASE2 ACTIVE_NOT_RECRUITING 2025-05-25 Memorial Sloan Kettering Cance... More >>r Center, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, 07748, United States|Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, 11725, United States|Memorial Sloan Kettering Westchester, Harrison, New York, 10604, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York, United States Less <<
NCT02792829 Healthy Volunteers PHASE1 COMPLETED 2025-08-14 Las Vegas, Nevada, United Stat... More >>es Less <<
NCT00280397 Cancer: Solid Tumors PHASE1 COMPLETED 2025-11-08 Tokyo, 104-0045, Japan
NCT06417606 Intrahepatic Cholangiocarcinom... More >>a Less << PHASE4 NOT_YET_RECRUITING 2025-05-30 Tongji Hospital, Wuhan, China
NCT04447755 Relapsed or Refractory Solid T... More >>umors Less << PHASE2 ACTIVE_NOT_RECRUITING 2025-02-14 Children's Hospital of Colorad... More >>o ( Site 0110), Aurora, Colorado, 80045, United States|Cleveland Clinic ( Site 0119), Cleveland, Ohio, 44195, United States|Monroe Carell Jr. Children's Hospital at Vanderbilt ( Site 0102), Nashville, Tennessee, 37232, United States|Mary Crowley Cancer Research Center ( Site 0107), Dallas, Texas, 75230, United States|Hospital Universitario Austral ( Site 0126), Pilar, Buenos Aires, B1629ODT, Argentina|Hospital de Ni?os Ricardo Gutiérrez ( Site 0125), Ciudad Autonoma de Buenos Aires, Caba, C1425EFD, Argentina|Sydney Children's Hospital ( Site 0801), Randwick, New South Wales, 2031, Australia|Queensland Children s Hospital ( Site 0804), Brisbane, Queensland, 4101, Australia|Royal Childrens Hospital Melbourne ( Site 0802), Parkville, Victoria, 3052, Australia|Perth Children s Hospital ( Site 0803), Nedlands, Western Australia, 6009, Australia|UZ Gent ( Site 0250), Gent, Oost-Vlaanderen, 9000, Belgium|Klinicki bolnicki centar Rijeka ( Site 0726), Rijeka, Primorsko-goranska Zupanija, 51000, Croatia|Klinika za djecje bolesti Zagreb ( Site 0725), Zagreb, Zagrebacka Zupanija, 10000, Croatia|Fakultni Nemocnice Brno Bohunice ( Site 0651), Brno, Brno-mesto, 613 00, Czechia|Fakultni nemocnice v Motole ( Site 0650), Praha 5, 150 06, Czechia|Centre Leon-Berard ( Site 0326), Lyon, Auvergne, 69008, France|Hopital La Timone ( Site 0328), Marseille, Bouches-du-Rhone, 13005, France|Gustave Roussy ( Site 0327), Villejuif, Val-de-Marne, 94800, France|Institut Curie ( Site 0325), Paris, 75005, France|Unidad Nacional de Oncologia Pediatrica ( Site 0176), Guatemala, 01011, Guatemala|Medi-K Cayala ( Site 0177), Guatemala, 01016, Guatemala|Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi OktatoKorhaz ( Site 0678), Miskolc, Borsod-Abauj-Zemplen, 3526, Hungary|Semmelweis University ( Site 0675), Budapest, 1094, Hungary|Debreceni Egyetem Klinikai Kozpont ( Site 0677), Debrecen, 4032, Hungary|Chaim Sheba Medical Center ( Site 0500), Ramat-Gan, 5265601, Israel|IRCCS Ospedale Pediatrico Bambino Gesu ( Site 0410), Rome, Roma, 00165, Italy|A.O.Universitaria Meyer-Oncology & Haematology Unit ( Site 0400), Firenze, Toscana, 50139, Italy|Istituto Giannina Gaslini ( Site 0411), Genova, 16147, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 0401), Milano, 20133, Italy|Ospedale Infantile Regina Margherita ( Site 0412), Torino, 10126, Italy|Asan Medical Center ( Site 0876), Songpagu, Seoul, 05505, Korea, Republic of|Seoul National University Hospital ( Site 0875), Seoul, 03080, Korea, Republic of|Starship Childrens Hospital ( Site 0826), Auckland, 1023, New Zealand|Clinica Anglo Americana ( Site 0203), San Isidro, Lima, 15073, Peru|Dmitry Rogachev National Research Center ( Site 0550), Moscow, Moskva, 117198, Russian Federation|St.Petersburg State Medical Univ. n.a. acad. I.P.Pavlov ( Site 0554), Saint Petersburg, Sankt-Peterburg, 197022, Russian Federation|Clinical Research Center of specialized types medical care-Oncology ( Site 0553), Saint-Petersburg, Sankt-Peterburg, 197758, Russian Federation|Institute for Oncology and Radiology of Serbia ( Site 0780), Belgrade, Beograd, 11000, Serbia|Univerzitetska decja klinika ( Site 0782), Beograd, 11000, Serbia|Wits Clinical Research ( Site 0579), Soweto, Gauteng, 2013, South Africa|Cancercare Rondebosch Oncology ( Site 0575), Cape Town, Western Cape, 7700, South Africa|Tygerberg Hospital ( Site 0578), Parow, Western Cape, 7505, South Africa|Hospital Universitario Sant Joan de Deu ( Site 0476), Esplugues de Llobregat, Barcelona, 08950, Spain|Hospital Nino Jesus ( Site 0477), Madrid, 28009, Spain|Skanes Universitetssjukhus Lund. ( Site 0525), Lund, Skane Lan, 221 85, Sweden|Hacettepe Universitesi Tip Fakultesi ( Site 0603), Ankara, 06100, Turkey|Istanbul Universitesi Onkoloji Enstitusu ( Site 0600), Istanbul, 34093, Turkey|Ege Universitesi Tip Fakultesi ( Site 0601), Izmir, 35040, Turkey|Dokuz Eylul Universitesi Arastirma Uygulama Hastanesi ( Site 0602), Izmir, 35330, Turkey Less <<
NCT03573960 Thyroid Neoplasms PHASE4 ACTIVE_NOT_RECRUITING 2024-12-30 All India Institute of Medical... More >> Sciences, New Delhi, Delhi, 110029, India|Indraprastha Apollo Hospital, New Delhi, Delhi, 110076, India|Shetty's Hospital, Bangalore, Karnataka, 560068, India|Regional Cancer Centre, RCC, Thiruvananthapuram, Thiruvananthapuram, Kerala, 695011, India|Deenanath Mangeshkar Hospital, Pune, Maharashtra, 411004, India|All India Institute of Medical Sciences, Bhubaneshwar, Odisa, 751019, India|S. P. Medical College & A. G. Hospitals, Bīkaner, Rajasthan, 334003, India|Tata Memorial Hospital, Mumbai, 400012, India|BL Kapoor Hospital, New Delhi, New Delhi, 110005, India|Indrayani Hospital, Alandi, Pune, 412105, India|City Cancer Centre, Vijayawada, 520002, India Less <<
NCT00946153 Hepatocellular Carcinoma PHASE1|PHASE2 COMPLETED 2015-08-13 Kashiwa-shi, Chiba, Japan|Kuru... More >>me-shi, Fukuoka, Japan|Sapporo-shi, Hokkaido, Japan|Kawasaki-shi, Kanagawa, Japan|Osaka-shi, Osaka, Japan|Osakasayama-shi, Osaka, Japan|Saga-shi, Saga, Japan|Chuo-ku, Tokyo, Japan|Minato-ku, Tokyo, Japan|Musashino-shi, Tokyo, Japan|Gangnam-gu, Seoul, Korea, Republic of|Songpa-gu, Seoul, Korea, Republic of Less <<
NCT02199392 P-glycoprotein|Healthy Volunte... More >>ers Less << PHASE1 COMPLETED 2025-01-12 Tacoma, Washington, 98418, Uni... More >>ted States Less <<
NCT03433703 Carcinoma, Hepatocellular PHASE2 TERMINATED 2019-01-07 California Liver Research Inst... More >>itute, Pasadena, California, 91105, United States|University of Florida, Gainesville, Florida, 32611, United States|University of Louisville, Louisville, Kentucky, 40202, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, 70121, United States Less <<
NCT06138769 Hepatocellular Carcinoma PHASE2 ACTIVE_NOT_RECRUITING 2027-11-01 Asan Medical Center, Seoul, 05... More >>505, Korea, Republic of Less <<
NCT05391867 Hepatocellular Carcinoma UNKNOWN 2023-06-30 Department of Hepatology, Dhak... More >>a, 1100, Bangladesh|Sir Salimullah Medical College, Dhaka, 1100, Bangladesh Less <<
NCT04008082 Carcinoma, Hepatocellular|Carc... More >>inoma|Neoplasms, Glandular and Epithelial|Neoplasms Less << COMPLETED 2022-01-28 Eisai Trial Site #1, Osaka, Ja... More >>pan|Eisai Trial Site #2, Tokyo, Japan Less <<
NCT02211222 Differentiated Thyroid Cancer APPROVED_FOR_MARKETING 2025-06-15 La Jolla, California, United S... More >>tates|Stanford, California, United States|Torrance, California, United States|Washington, District of Columbia, United States|Chicago, Illinois, United States|Boston, Massachusetts, United States|Lansing, Michigan, United States|Lebanon, New Hampshire, United States|Neptune, New Jersey, United States|Cleveland, Ohio, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Houston, Texas, United States Less <<
NCT02726503 Anaplastic Thyroid Cancer PHASE2 COMPLETED 2020-03-20 Nagoya University Hospital, Na... More >>goya-city, Aichi-prefecture, 466-8560, Japan|Fujita Health University Hospital, Toyoake-city, Aichi-prefecture, 470-1192, Japan|IUHW Ichikawa Hospital, Ichikawa-city, Chiba-prefecture, 272-0827, Japan|National Cancer Center Hospital East, Kashiwa-city, Chiba-prefecture, 277-8577, Japan|Japanese Red Cross Narita Hospital, Narita-city, Chiba-prefecture, 286-8523, Japan|Kuma Hospital, Kobe-city, Hyogo-prefecture, 650-0011, Japan|Kobe Univbersity Hospital, Kobe-city, Hyogo-prefecture, 650-0017, Japan|University of Tsukuba Hospital, Tsukuba-city, Ibaraki-prefecture, 305-8576, Japan|Iwate Medical University Hospital, Morioka-city, Iwate-prefecture, 020-8505, Japan|Kitasato University Hospital, Sagamihara-city, Kanagawa-prefecture, 252-0375, Japan|Showa University Northern Yokohama Hospital, Yokohama-city, Kanagawa-prefecture, 224-8503, Japan|Kanagawa Cancer Center, Yokohama-city, Kanagawa-prefecture, 241-8515, Japan|Miyaghi Cancer Center, Natori-city, Miyagi-prefecture, 981-1293, Japan|Tohoku University Hospital, Sendai-city, Miyagi-prefecture, 980-8574, Japan|Shinsyu University School of Medicine Department of Surgery, Matsumoto-city, Nagano-prefecture, 390-8621, Japan|Nara Hospital Kinki University Faculty of Medicine, Ikoma-city, Nara-prefecture, 630-0293, Japan|Nara Medical University, Kashihara-city, Nara-prefecture, 634-8522, Japan|Osaka Police Hospital, Osaka-city, Osaka-prefecture, 543-0035, Japan|Osaka City University Graduate School of Medicine and Faculty of Medicine, Osaka-city, Osaka-prefecture, 545-8585, Japan|Nippon Medical School Hospital, Bunkyo-ku, Tokyo-metropolis, 113-8603, Japan|The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo-metropolis, 135-8550, Japan|Ito Hospital, Shibuya-ku, Tokyo-metropolis, 150-8308, Japan|Tokyo Medical University Hospital, Shinjuku-ku, Tokyo-metropolis, 160-0023, Japan Less <<
NCT00121719 Solid Tumor or Lymphoma PHASE1 COMPLETED 2019-03-01 Netherlands Cancer Institute- ... More >>Antoni Van Leeuwenhoek Hospital, Amsterdam, 1066 Cx, Netherlands|Gartnavel General Hospital, Glasgow, G12 0Yn, United Kingdom Less <<
NCT02860936 Adenoid Cystic Carcinomas of t... More >>he Salivary Glands Less << PHASE2 COMPLETED 2025-06-19 Fondazione IRCCS Istituto Nazi... More >>onale dei Tumori, Milan, 20133, Italy Less <<
NCT01111461 Endometrial Cancer PHASE2 COMPLETED 2025-10-15 Phoenix, Arizona, United State... More >>s|Scottsdale, Arizona, United States|Tucson, Arizona, United States|Los Angeles, California, United States|Honolulu, Hawaii, United States|Arlington Heights, Illinois, United States|Niles, Illinois, United States|Boston, Massachusetts, United States|Detroit, Michigan, United States|Burnsville, Minnesota, United States|Edina, Minnesota, United States|Maplewood, Minnesota, United States|Minneapolis, Minnesota, United States|Saint Paul, Minnesota, United States|Woodbury, Minnesota, United States|Saint Louis, Missouri, United States|Morristown, New Jersey, United States|New York, New York, United States|Chapel Hill, North Carolina, United States|Cleveland, North Carolina, United States|Durham, North Carolina, United States|Winston-Salem, North Carolina, United States|Eugene, Oregon, United States|Portland, Oregon, United States|Springfield, Oregon, United States|Tualatin, Oregon, United States|Charleston, South Carolina, United States|Austin, Texas, United States|Bedford, Texas, United States|Dallas, Texas, United States|Fort Worth, Texas, United States|Tyler, Texas, United States|Newport News, Virginia, United States|Norfolk, Virginia, United States|Virginia Beach, Virginia, United States|Vancouver, Washington, United States|Arlon, Belgium|Charleroi, Belgium|Duffel, Belgium|Ghent, Belgium|Kortrijk, Belgium|Leuven, Belgium|Liege, Belgium|Namur, Belgium|Oostende, Belgium|Roeselare, Belgium|Yvoir, Belgium|Pleven, Bulgaria|Plovdiv, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Veliko Tarnovo, Bulgaria|Budapest, Hungary|Gyor, Hungary|Lublin, Poland|Poznan, Poland|Warsaw, Poland|Brasov County, Romania|Bucharest, Romania|Cluj County, Romania|Dolj County, Romania|Kazan, Russian Federation|Nizhny Novgorod, Russian Federation|Orenburg, Russian Federation|Petersburg, Russian Federation|Pyatigorsk, Russian Federation|Sochi,, Russian Federation|St. Petersburg, Russian Federation|Stavropol, Russian Federation|Syktyvkar, Russian Federation|Tomsk, Russian Federation|Tula, Russian Federation|Ufa, Russian Federation|Vladivostok, Russian Federation|Chernihiv, Ukraine|Donetsk, Ukraine|Kharkiv, Ukraine|Kyiv, Ukraine|Zaporizhia, Ukraine Less <<
NCT04415567 Hepatocellular Carcinoma COMPLETED 2020-03-31 Xinhua Hospital Affiliated to ... More >>Shanghai Jiao Tong University Medical School, Shanghai, 200092, China Less <<
NCT02678780 Neuroendocrine Tumors PHASE2 COMPLETED 2025-08-20 Universit?tsklinik für Innere ... More >>Medizin, Graz, 8036, Austria|Medizinische Universit?t Wien, Wien, a-1090, Austria|Spedali Civili di Brescia, Brescia, Italy|Instituto Oncologico Mediterraneo, Catania, Italy|Azienda Ospedaliero Universitaria Careggi - SC di Oncologia, Firenze, 50139, Italy|IRST of Meldola, Meldola, Italy|Istituto Europeo di Oncologia - Unità di Oncologia Medica Gastrointestinale e Tumori Neuroendocrini, Milano, 20141, Italy|AOU Policlinico di Modena - DH Oncologico, Modena, 41124, Italy|IRCCS Napoli, Napoli, Italy|Hospital Universatorio de Verona, Verona, Italy|Hospital Virgen de la Victoria, Málaga, Andalucía, 29010, Spain|Hospital Central de Asturias, Oviedo, Asturias, 33006, Spain|Hospital Marqués de Valdecilla, Santander, Cantabria, 39011, Spain|Hospital de Donostia, Donostia, País Vasco, Spain|Hospital Universitario Vall Hebrón, Barcelona, 08035, Spain|ICO Hospitalet, L′Hospitalet de Llobregat, 08908, Spain|Hospital Universitario Ramón y Cajal, Madrid, 28034, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Hospital Universitario la Paz, Madrid, 28046, Spain|Hospital Miguel Servet, Zaragoza, 50009, Spain|Beatson Oncology Centre Gartnavel General Hospital, Glasgow, G12 0YN, United Kingdom|Christie Hospital, Manchester, Manchester, M20 4BX, United Kingdom Less <<
NCT04053972 Hepatocellular Carcinoma PHASE3 UNKNOWN 2022-12-31 SUN YAT-SEN University Cancer ... More >>Center, Guangzhou, Guangdong, 510060, China Less <<
NCT04656249 Cholangiocarcinoma|Biliary Tra... More >>ct Cancer|Targeted Therapy Less << PHASE2 COMPLETED 2021-05-01 Chinese Academy of Medical Sci... More >>ences & Peking Union Medical College Hospital, Beijing, Beijing, 100730, China Less <<
NCT02199379 Renal Impairment|Disease Sever... More >>ity Less << PHASE1 COMPLETED 2025-10-12 Orlando, Florida, 32809, Unite... More >>d States|Minneapolis, Minnesota, 55404, United States|Knoxville, Tennessee, 37920, United States Less <<
NCT02430714 Thyroid Neoplasms COMPLETED 2016-11-06 Osaka, Japan|Tokyo, Japan
NCT03663114 Carcinoma, Hepatocellular COMPLETED 2020-02-20 Eisai trial site 1, Osaka, Jap... More >>an|Eisai trial site 2, Tokyo, Japan Less <<
NCT00121680 Metastatic Melanoma PHASE1 COMPLETED 2025-05-15 Dallas, Texas, United States|H... More >>ouston, Texas, United States Less <<
NCT04297254 Carcinoma, Hepatocellular PHASE4 COMPLETED 2023-07-31 HCG Comprehensive Cancer Care ... More >>Hospital, Bangalore, Karnataka, 560027, India|Tata Memorial Hospital, Mumbai, Maharashtra, 400012, India|HCG Manavata Cancer Centre, Nashik, Maharashtra, 422002, India|Shatabdi Hospital, Nashik, Maharashtra, 422005, India|Apex Wellness Hospital, Nashik, Maharashtra, 422009, India|LMMF's Deenanath Mangeshkar Hospital & Research Center, Pune, Maharashtra, 411004, India|Noble Hospital, Pune, Maharashtra, 411013, India|Somani Hospital, Jaipur, Rajasthan, 302019, India|Meenakshi Mission Hospital, Madurai, Tamil Nadu, 625107, India|Apollo Gleneagles Hospital Limited, Kolkata, West Bengal, 700054, India Less <<
NCT01268293 Cancer PHASE1 COMPLETED 2025-04-13 Chuo-ku, Tokyo, Japan
NCT02579616 Biliary Tract Cancer PHASE2 COMPLETED 2019-02-27 Nagoya, Aichi, Japan|Kashiwa, ... More >>Chiba, Japan|Yokohama, Kanagawa, Japan|Ina-machi, Saitama, Japan|Chuo-ku, Tokyo, Japan|Koto-ku, Tokyo, Japan|Mitaka, Tokyo, Japan Less <<
NCT05221775 First-line Treatment|Advanced ... More >>Gastric Carcinoma Less << PHASE1 UNKNOWN 2023-10-01 Tianjin Medical University Can... More >>cer Institute and Hospital, Tianjin, China Less <<
NCT02846766 Cancer PHASE2 WITHDRAWN 2021-06-01 University of California, San ... More >>Diego, La Jolla, California, 92093, United States|Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, 60611, United States Less <<
NCT04428437 Hepatocellular Carcinoma TERMINATED 2023-09-30 Humanity & Health Clinical Tri... More >>al Centre, Hong Kong, Hong Kong SAR, Hong Kong Less <<
NCT02578316 Advanced Solid Tumors|Lymphoma... More >>s Less << PHASE1 COMPLETED 2025-10-10 Amsterdam, Netherlands
NCT05789667 Differentiated Thyroid Cancer|... More >>Gender Less << RECRUITING 2025-12-31 Regina Elena National Cancer I... More >>nstitute, Rome, 00144, Italy Less <<
NCT01877083 KIF5B-RET-Positive Adenocarcin... More >>oma of the Lung Less << PHASE2 COMPLETED 2017-11-02 Duarte, California, United Sta... More >>tes|La Jolla, California, United States|Whittier, California, United States|Jacksonville, Florida, United States|Canton, Ohio, United States|Cleveland, Ohio, United States|Knoxville, Tennessee, United States|Dallas, Texas, United States|Hong Kong, Hong Kong|Sha Tin, Hong Kong|Nagoya, Aichi, Japan|Kashiwa, Chiba, Japan|Akashi, Hyogo, Japan|Kobe, Hyogo, Japan|Natori, Miyagi, Japan|Osaka-Sayama, Osaka, Japan|Chuo-ku, Tokyo, Japan|Koto-Ku, Tokyo, Japan|Fukuoka, Japan|National Cancer Center Hospital, Singapore, Singapore|National University Hospital, Singapore, Singapore|National Taiwan University Hospital, Taipei, Taiwan|Veterans General Hospital Taipei, Taipei, Taiwan Less <<
NCT03533361 Thyroid Cancer APPROVED_FOR_MARKETING - Hospital Sirio Libanes, Sao Pa... More >>ulo, S?o Paulo, 01246-000, Brazil Less <<
NCT05901194 Hepatocellular Carcinoma Non-r... More >>esectable Less << PHASE1|PHASE2 NOT_YET_RECRUITING 2025-07-27 Hospital Haut levêque, Bordeau... More >>x, France|Hospital Henri Mondor, Créteil, France|Hospital Claude Huriez, Lille, France|Pontchaillou Hospital, Rennes, France|Hospital Trousseau, Tours, France|Paul Brousse Hospital, Villejuif, France Less <<
NCT03801499 Intrahepatic Cholangiocarcinom... More >>a Less << PHASE2 WITHDRAWN 2025-12-19 Cancer Center Sun Yat-sen Univ... More >>ersity, Guangzhou, Guangdong, 510060, China Less <<
NCT02953743 Unresectable Hepatocellular Ca... More >>rcinoma (HCC) Less << PHASE1 COMPLETED 2020-12-28 Harbin Medical University Canc... More >>er Hospital, Harbin, Heilongjiang, China|Shanghai Cancer Hospital, Fudan University, Shanghai, Shanghai, China|Zhongshan Hospital Fudan University, Shanghai, Shanghai, China Less <<
NCT02421042 Hepatic Impairment|Hepatic Fun... More >>ction Less << PHASE1 COMPLETED 2025-07-12 Miami, Florida, 33014, United ... More >>States|Miami, Florida, 33169, United States|Orlando, Florida, 32809, United States|Minneapolis, Minnesota, 55404, United States|Knoxville, Tennessee, 37920, United States Less <<
NCT03506048 Differentiated Thyroid Gland C... More >>arcinoma|Thyroid Gland Follicular Carcinoma|Thyroid Gland Papillary Carcinoma Less << PHASE2 TERMINATED 2021-06-24 Emory University Hospital/Wins... More >>hip Cancer Institute, Atlanta, Georgia, 30322, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.34mL

0.47mL

0.23mL

11.71mL

2.34mL

1.17mL

23.43mL

4.69mL

2.34mL

References

 

Historical Records

Categories